ARTICLE | Company News
Immunomedics other research news
September 16, 1996 7:00 AM UTC
IMMU received a $670,000 Phase II SBIR grant from the NIH to develop a treatment for non-Hodgkin's lymphoma using its LL2 humanized MAb. The company will conduct a Phase II trial of the MAb attached t...